Geneplus-Beijing Co. Ltd.

13 clinical trials · Sponsor

Record	Firm	Date
Timing of ctDNA Testing in Advanced Breast Cancer (NCT07681323)	Geneplus-Beijing Co. Ltd.	2026-07-08
Application of CfDNA Methylation Detection in Auxiliary Diagnosis of Breast Cancer (NCT06876610)	Geneplus-Beijing Co. Ltd.	2025-03-15
The Exploration of Personalized ctDNA Based MRD in the Clinical Significance of Cervical Cancer (NCT06283875)	Geneplus-Beijing Co. Ltd.	2024-12-01
Circulating Tumor DNA (ctDNA) as a Predictive Biomarker for Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H Colorectal Patients (NCT06098560)	Geneplus-Beijing Co. Ltd.	2023-10-30
Exploration of Predictive Markers of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer (NCT05965557)	Geneplus-Beijing Co. Ltd.	2023-06-19
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer (NCT05292443)	Geneplus-Beijing Co. Ltd.	2021-12-20
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients (NCT04566432)	Geneplus-Beijing Co. Ltd.	2020-07-01
ctDNA Monitoring in Early Breast Cancer (NCT04353557)	Geneplus-Beijing Co. Ltd.	2019-11-29
The PREDICT Study: Prospective Early Detection In a Population at High-risk for Common Malignant Tumor (NCT04405557)	Geneplus-Beijing Co. Ltd.	2019-11-12
Assessment of the Minimal Residual Disease in Ovarian Cancer From Circulating Tumor DNA and Immune Repertoire (NCT03614689)	Geneplus-Beijing Co. Ltd.	2017-11-25

Every clearance here is in the API, with alerts when new ones post.